• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

如何管理高剂量化疗和自体干细胞移植中动员效果不佳的患者?

How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation?

作者信息

Ataca Atilla Pinar, Bakanay Ozturk Sule Mine, Demirer Taner

机构信息

Department of Hematology, Ankara University Medical School, Cebeci, 06590 Ankara, Turkey.

Department of Hematology, Ankara Ataturk Hospital, Cankaya, 06800 Ankara, Turkey.

出版信息

Transfus Apher Sci. 2017 Apr;56(2):190-198. doi: 10.1016/j.transci.2016.11.005. Epub 2016 Dec 26.

DOI:10.1016/j.transci.2016.11.005
PMID:28034547
Abstract

Today, peripheral blood stem cells are the preferred source of stem cells over bone marrow. Therefore, mobilization plays a crutial role in successful autologous stem cell transplantation. Poor mobilization is generally defined as failure to achieve the target level of at least 2×10 CD34 cells/kg body weight. There are several strategies to overcome poor mobilization: 1) Larger volume Leukapheresis (LVL) 2) Re-mobilization 3) Plerixafor 4) CM+Plerixafor (P)+G-CSF and 5) Bone Marrow Harvest. In this review, the definitions of successful and poor mobilization are discussed. Management strategies for poor mobilization are defined. The recent research on new agents are included.

摘要

如今,外周血干细胞是比骨髓更优选的干细胞来源。因此,动员在成功的自体干细胞移植中起着至关重要的作用。动员不佳通常定义为未能达到至少2×10 CD34细胞/千克体重的目标水平。有几种策略可克服动员不佳的情况:1)大容量白细胞分离术(LVL);2)再次动员;3)普乐沙福;4)环磷酰胺+普乐沙福(P)+粒细胞集落刺激因子(G-CSF);5)骨髓采集。在本综述中,讨论了成功动员和动员不佳的定义。明确了动员不佳的管理策略。还纳入了关于新药物的最新研究。 (注:原文中“2×10 CD34 cells/kg body weight”表述有误,可能是“2×10⁶ CD34 cells/kg body weight” )

相似文献

1
How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation?如何管理高剂量化疗和自体干细胞移植中动员效果不佳的患者?
Transfus Apher Sci. 2017 Apr;56(2):190-198. doi: 10.1016/j.transci.2016.11.005. Epub 2016 Dec 26.
2
Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor.优化难动员患者的动员策略:普乐沙福的作用。
Transfus Apher Sci. 2015 Aug;53(1):23-9. doi: 10.1016/j.transci.2015.05.011. Epub 2015 Jun 9.
3
Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.自体干细胞动员时使用普乐沙福抢救后的患者结局:单中心回顾性分析
Transfusion. 2017 Jan;57(1):115-121. doi: 10.1111/trf.13883. Epub 2016 Nov 18.
4
Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.外周血造血干细胞移植供者单用粒细胞集落刺激因子(G-CSF)或 G-CSF 联合培非格司亭动员后造血干细胞的细胞成分差异。
Biol Blood Marrow Transplant. 2018 Nov;24(11):2171-2177. doi: 10.1016/j.bbmt.2018.06.023. Epub 2018 Jun 21.
5
Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.培洛昔福联合粒细胞集落刺激因子(G-CSF)治疗淋巴瘤和多发性骨髓瘤患者:在自体造血干细胞动员时,G-CSF 联合或不联合化疗失败后的奥地利经验
Transfusion. 2011 May;51(5):968-75. doi: 10.1111/j.1537-2995.2010.02896.x. Epub 2010 Sep 28.
6
Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.普乐沙福作为一种抢先治疗策略,在自体干细胞动员失败的情况下成功率很高。
J Clin Apher. 2017 Aug;32(4):224-234. doi: 10.1002/jca.21496. Epub 2016 Aug 31.
7
European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization.欧洲非血液病患者使用培洛昔康动员干细胞的数据:欧洲干细胞动员联合会的分析。
Transfusion. 2012 Nov;52(11):2395-400. doi: 10.1111/j.1537-2995.2012.03603.x. Epub 2012 Mar 13.
8
Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.普乐沙福用于挽救性干细胞动员可减少多发性骨髓瘤患者白细胞分离术的使用。
J Clin Apher. 2014 Dec;29(6):299-304. doi: 10.1002/jca.21323. Epub 2014 Apr 26.
9
Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.成人自体外周血干细胞移植中动员不佳的发生率及危险因素:单中心经验
Vox Sang. 2014 Nov;107(4):407-15. doi: 10.1111/vox.12183. Epub 2014 Jul 31.
10
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.培洛昔福联合粒细胞集落刺激因子与安慰剂联合粒细胞集落刺激因子动员多发性骨髓瘤且外周血 CD34+细胞计数低的患者中的 CD34+造血干细胞:一项随机试验的亚组分析结果。
Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.

引用本文的文献

1
Impact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study.达雷妥尤单抗联合硼替佐米、沙利度胺和地塞米松诱导治疗对接受自体干细胞移植的新诊断多发性骨髓瘤患者干细胞动员结果的影响:一项多中心研究
Ann Hematol. 2025 Sep 5. doi: 10.1007/s00277-025-06581-x.
2
Is neutropenic fever an obstacle to effective stem cell harvesting?中性粒细胞减少性发热是有效采集干细胞的障碍吗?
Asian J Transfus Sci. 2024 Jan-Jun;18(1):21-26. doi: 10.4103/ajts.ajts_152_21. Epub 2022 Sep 28.
3
Stem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges.
成人自体/异体移植中的干细胞采集和动员:关键点和未来挑战。
Cells. 2024 Mar 28;13(7):586. doi: 10.3390/cells13070586.
4
Pre-mobilization platelet count predicts stem cell yield during mobilization in patients with multiple myeloma.动员前血小板计数可预测多发性骨髓瘤患者动员期间的干细胞产量。
Cancer Pathog Ther. 2022 Dec 6;1(1):40-45. doi: 10.1016/j.cpt.2022.11.004. eCollection 2023 Jan.
5
On-demand plerixafor added to high-dose cyclophosphamide and pegylated recombinant human granulocyte colony-stimulating factor in the mobilization of patients with multiple myeloma: a treatment with high effectiveness, convenient, and affordable cost.在多发性骨髓瘤患者动员中,按需添加普乐沙福至高剂量环磷酰胺和聚乙二醇化重组人粒细胞集落刺激因子:一种高效、便捷且成本可承受的治疗方法。
Front Oncol. 2024 Jan 17;13:1306367. doi: 10.3389/fonc.2023.1306367. eCollection 2023.
6
A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation.一项关于德国范围内多发性骨髓瘤动员不佳患者在自体干细胞移植前造血干细胞动员与采集的系统性研究。
Transfus Med Hemother. 2023 Oct 16;50(6):475-490. doi: 10.1159/000531935. eCollection 2023 Dec.
7
Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study.淋巴瘤动员不佳患者的动员及造血干细胞采集:德国OPTIMOB研究的最终结果
Transfus Med Hemother. 2023 Sep 21;50(5):403-416. doi: 10.1159/000531936. eCollection 2023 Oct.
8
Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments.多发性骨髓瘤中的干细胞动员:挑战、策略和最新进展。
Ann Hematol. 2023 May;102(5):995-1009. doi: 10.1007/s00277-023-05170-0. Epub 2023 Mar 22.
9
Hematopoietic stem cell mobilization.造血干细胞动员
Tzu Chi Med J. 2021 Oct 21;34(3):270-275. doi: 10.4103/tcmj.tcmj_98_21. eCollection 2022 Jul-Sep.
10
Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update.普乐沙福在自体和异基因干细胞移植中用于干细胞动员的应用:最新进展
J Blood Med. 2021 Jun 2;12:403-412. doi: 10.2147/JBM.S307520. eCollection 2021.